All In Biotech

Free tool

FAERS Monitor: Ekterly

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219301 or its brand name (Ekterly, Sebetralstat). Reports on generic versions are filed under their own applications.

Reports

539

Serious

191

35% of reports

Hospitalization

95

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema218
  • drug ineffective102
  • incorrect dose administered47
  • headache36
  • stress30
  • product dose omission issue22
  • weight increased22
  • weight decreased19
  • vomiting18
  • nausea15
  • off label use14
  • dizziness13
  • fall13
  • malaise13
  • pruritus13

Reports by year received

View as table
YearReports
20211
20222
20233
20248
202582
2026443

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal218809.1729.0171,679
stressSignal3016.211.5415
incorrect dose administeredSignal478.06.1286
weight increasedSignal223.82.544
drug ineffectiveSignal1023.02.5145
product dose omission issueSignal222.91.926
weight decreasedSignal192.71.718
headacheSignal362.21.624
fall131.50.92
vomiting181.50.93
pruritus131.30.81
malaise131.20.70
dizziness131.00.60
nausea150.70.41
off label use140.60.43

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.